Form 4: Leap Therapeutics Chief Scientific Officer Settles Restricted Stock Units
SEC Form 4 Filing
Jason Baum, Chief Scientific Officer of Leap Therapeutics, settles restricted stock units, resulting in the issuance and withholding of common stock to cover tax obligations.
Summary
- On March 28, 2025, Jason Baum, the Chief Scientific Officer of Leap Therapeutics, settled 22,500 restricted stock units (RSUs) that were previously granted on January 31, 2022.
- The settlement was done on a net issue basis, meaning that instead of receiving all 22,500 shares, Mr. Baum received 15,896 shares, while 6,604 shares were withheld by the company to cover tax obligations.
- The original grant of RSUs was subject to a 10-for-1 reverse stock split that occurred on June 20, 2023.
- The RSUs vested on January 31, 2025, but the settlement was deferred by the Compensation Committee until March 28, 2025, due to potential insider trading policy restrictions.
- The RSUs would have been forfeited if Mr. Baum's employment had terminated before the vesting date of January 31, 2022.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a routine transaction related to executive compensation. The deferral of settlement due to insider trading policy considerations is a sign of good governance.
Positives
- The settlement of RSUs indicates continued employment and vesting of benefits for a key executive.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the biotechnology industry to attract and retain talent.
- Net issuance of shares to cover tax obligations is a standard method for settling RSUs.
- Deferral of RSU settlement due to insider trading policies is a prudent measure to ensure compliance with securities laws.
Stakeholder Impact
- The settlement of RSUs impacts the company's share structure and potentially shareholder equity.
Key Dates
| Date | Description |
|---|---|
| January 31, 2022 | Date of original RSU grant |
| June 20, 2023 | Date of 10-for-1 reverse stock split |
| January 31, 2025 | RSUs vested |
| March 28, 2025 | RSU settlement date |
| April 01, 2025 | Date of Form 4 filing |
Keywords
Restricted Stock Units, RSUs, Form 4, Insider Trading, Stock Settlement, Leap Therapeutics, Jason Baum, Compensation Committee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.